{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:46Z","timestamp":1793946526643,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105457","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:41:56Z","timestamp":1782492116000},"page":"105457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Amino acid metabolic reprogramming in immunotherapy for hepatocellular carcinoma: Adaptive resistance, patient stratification, and longitudinal monitoring"],"prefix":"10.1016","volume":"226","author":[{"given":"Hongyang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocan","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4812-3494","authenticated-orcid":false,"given":"Shumin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2026.105457_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105457_bib2","first-page":"749","article-title":"Folated-nanocarrier for paclitaxel drug delivery in leukemia cancer therapy","volume":"10","author":"Al-Musawi","year":"2018","journal-title":"J. Pharm. Sci. Res."},{"key":"10.1016\/j.critrevonc.2026.105457_bib3","doi-asserted-by":"crossref","DOI":"10.1063\/5.0092330","article-title":"Nanoformulation of intelligence polymeric nanocarrier for resveratrol targeted delivery and study its cytotoxic, apoptotic, and genetics effects in epidermoid carcinoma therapy","volume":"2437","author":"Alnasraui","year":"2022","journal-title":"AIP Conf. Proc."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40364-025-00844-5","article-title":"Molecular network of metabolic reprogramming and precision diagnosis and treatment of hepatocellular carcinoma","volume":"13","author":"An","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105457_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1241677","article-title":"Identification of a prognostic evaluator from glutamine metabolic heterogeneity studies within and between tissues in hepatocellular carcinoma","volume":"14","author":"Bao","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105457_bib6","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-24-3180","article-title":"SLC3A2-mediated lysine uptake by cancer cells restricts t-cell activity in hepatocellular carcinoma","volume":"85","author":"Chang","year":"2025","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib7","doi-asserted-by":"crossref","first-page":"295S","DOI":"10.1093\/jn\/136.1.295S","article-title":"Branched-chain amino acid enriched supplements as therapy for liver disease","volume":"136","author":"Charlton","year":"2006","journal-title":"J. Nutr."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105457_bib8","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.3390\/ijms222111661","article-title":"Aberrant upregulation of indoleamine 2,3-dioxygenase 1 promotes proliferation and metastasis of hepatocellular carcinoma cells via coordinated activation of ahr and \u03b2-catenin signaling","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105457_bib9","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.3390\/cells11233924","article-title":"Unbalanced Glutamine Partitioning between CD8+ T cells and cancer cells accompanied by immune cell dysfunction in hepatocellular carcinoma","volume":"11","author":"Chen","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib10","doi-asserted-by":"crossref","first-page":"7654","DOI":"10.1038\/s41467-024-51882-w","article-title":"Citrullination modulation stabilizes HIF-1\u03b1 to promote tumour progression","volume":"15","author":"Chen","year":"2024","journal-title":"Nat. Commun."},{"issue":"52","key":"10.1016\/j.critrevonc.2026.105457_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203894119","article-title":"Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105457_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.715905","article-title":"Hepatocellular Carcinoma Cells Are Protected From Immunolysis by Mesenchymal Stromal Cells Through Indoleamine 2,3 Dioxygenase","volume":"9","author":"Chinnadurai","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41420-021-00666-y","article-title":"ERRFI1 induces apoptosis of hepatocellular carcinoma cells in response to tryptophan deficiency","volume":"7","author":"Cui","year":"2021","journal-title":"Cell. Death Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105457_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"de Galarreta","year":"2019","journal-title":"Cancer Discov."},{"issue":"6 1","key":"10.1016\/j.critrevonc.2026.105457_bib15","doi-asserted-by":"crossref","first-page":"1579S","DOI":"10.1093\/jn\/137.6.1579S","article-title":"Aromatic amino acid metabolism during liver failure","volume":"137","author":"Dejong","year":"2007","journal-title":"J. Nutr."},{"key":"10.1016\/j.critrevonc.2026.105457_bib16","article-title":"Glutamine synthetase loss in \u03b2-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming","author":"Delgado","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105457_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","article-title":"Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma","volume":"12","author":"Du","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105457_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217680","article-title":"The arginine metabolism and its deprivation in cancer therapy","volume":"620","author":"Feng","year":"2025","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105457_bib19","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105457_bib20","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.3390\/ijms24087463","article-title":"Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses","volume":"24","author":"Foglia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105457_bib21","article-title":"Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications","volume":"16","author":"Gao","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105457_bib22","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/ijms21124414","article-title":"Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy","volume":"21","author":"Giannone","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105457_bib23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cell.2025.11.034","article-title":"Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity","volume":"189","author":"Gu","year":"2026","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2326-6066.CIR-19-0040","article-title":"Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers","volume":"8","author":"Hoffmann","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105457_bib25","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.3390\/ijms25115584","article-title":"The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma","volume":"25","author":"Hu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105457_bib26","article-title":"High Expression of TGF-\u03b21 Contributes to Hepatocellular Carcinoma Prognosis via Regulating Tumor Immunity","volume":"12","author":"Jin","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105457_bib27","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.cmet.2019.03.005","article-title":"Transmembrane 4 L Six Family Member 5 Senses Arginine for mTORC1 Signaling","volume":"29","author":"Jung","year":"2019","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13046-021-01912-y","article-title":"Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK\/eIF2\u03b1\/ATF4\/CHOP axis in hepatocellular carcinoma","volume":"40","author":"Kim","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib29","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1038\/s41467-023-42360-w","article-title":"Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma","volume":"14","author":"Leung","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-026-02578-w","article-title":"Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities","volume":"25","author":"Li","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105457_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1066773","article-title":"Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105457_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1185985","article-title":"Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105457_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00262-020-02697-3","article-title":"The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma","volume":"70","author":"Liu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105457_bib34","article-title":"Dysregulated arginine metabolism is associated with pro-tumor neutrophil polarization in liver cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105457_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1186\/s12967-025-07056-3","article-title":"Multi-omics profiling reveals downregulated tumor lysine metabolism reshaping the immune microenvironment and therapeutic responses in hepatocellular carcinoma","volume":"23","author":"Lu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105457_bib37","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/hep.31864","article-title":"Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma","volume":"74","author":"Luo","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105457_bib38","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cmet.2022.06.010","article-title":"GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment","volume":"34","author":"Missiaen","year":"2022","journal-title":"Cell. Metab."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105457_bib39","doi-asserted-by":"crossref","first-page":"13590","DOI":"10.3390\/ijms252413590","article-title":"Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma","volume":"25","author":"Oura","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105457_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157410","article-title":"Creatine riboside is a cancer cell-derived metabolite associated with arginine auxotrophy","volume":"132","author":"Parker","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105457_bib41","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.3390\/ijms20174131","article-title":"Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function","volume":"20","author":"Pi\u00f1eiro Fern\u00e1ndez","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105457_bib42","article-title":"Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma","volume":"6","author":"Qi","year":"2023","journal-title":"Res. (Wash. D. C. )"},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105457_bib43","doi-asserted-by":"crossref","first-page":"15355","DOI":"10.1039\/D5SC03778F","article-title":"Novel tryptophan 2,3-dioxygenase-targeted ruthenium(ii)-indole complex activates immunotherapy in vitro and in vivo","volume":"16","author":"Shen","year":"2025","journal-title":"Chem. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.apsb.2024.10.016","article-title":"Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8(+) T-cell-mediated antitumor immunity in liver cancer","volume":"15","author":"Sun","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105457_bib45","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1007\/s12072-023-10544-7","article-title":"Targeting NAD(+) metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression","volume":"17","author":"Sun","year":"2023","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s42255-025-01430-7","article-title":"Chronic stress drives liver cancer by impairing the hepatic kynurenine pathway and immune surveillance","volume":"8","author":"Sun","year":"2026","journal-title":"Nat. Metab."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105457_bib47","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3390\/ijms26030968","article-title":"Role of Kynurenine and Its Derivatives in Liver Diseases: Recent Advances and Future Clinical Perspectives","volume":"26","author":"Tan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105457_bib48","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ccell.2025.03.011","article-title":"Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures","volume":"43","author":"Tang","year":"2025","journal-title":"Cancer Cell."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105457_bib49","article-title":"Role of ammonia in NAFLD: An unusual suspect","volume":"5","author":"Thomsen","year":"2023","journal-title":"JHEP Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105457_bib50","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.3390\/ijms24032652","article-title":"The Role of PI3K\/AKT\/mTOR Signaling in Hepatocellular Carcinoma Metabolism","volume":"24","author":"Tian","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105457_bib51","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/cells10123469","article-title":"Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism","volume":"10","author":"Tr\u00e9z\u00e9guet","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105457_bib52","article-title":"Arginine-Loaded Nano-Calcium-Phosphate-Stabilized Lipiodol Pickering Emulsions Potentiates Transarterial Embolization-Immunotherapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105457_bib53","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1158\/0008-5472.CAN-17-0090","article-title":"Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105457_bib54","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1172\/JCI75836","article-title":"Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis","volume":"125","author":"Xiang","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13062-024-00567-x","article-title":"A glutamine metabolism-associated prognostic model to predict prognosis and therapeutic responses of hepatocellular carcinoma","volume":"19","author":"Xu","year":"2024","journal-title":"Biol. Direct"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib56","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12935-022-02730-8","article-title":"Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes","volume":"22","author":"Xue","year":"2022","journal-title":"Cancer Cell. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13046-019-1083-5","article-title":"H2S suppresses indoleamine 2, 3-dioxygenase 1 and exhibits immunotherapeutic efficacy in murine hepatocellular carcinoma","volume":"38","author":"Yang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105457_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111691","article-title":"Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression","volume":"41","author":"Yang","year":"2022","journal-title":"Cell. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105457_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gutjnl-2024-332429","article-title":"Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A(+) myeloid cells to promote liver cancer progression","volume":"74","author":"Yang","year":"2025","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-026-00427-2","article-title":"Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities","volume":"7","author":"Yu","year":"2026","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105457_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12967-024-05298-1","article-title":"Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105457_bib62","doi-asserted-by":"crossref","first-page":"7986","DOI":"10.1021\/acs.analchem.5c00384","article-title":"Development of a Single-Cell Spatial Metabolomics Method for the Characterization of Cell-Cell Metabolic Interactions","volume":"97","author":"Zhang","year":"2025","journal-title":"Anal. Chem."},{"key":"10.1016\/j.critrevonc.2026.105457_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.731790","article-title":"Identification and Validation of a Nine-Gene Amino Acid Metabolism-Related Risk Signature in HCC","volume":"9","author":"Zhao","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105457_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1697675","article-title":"Immune cell metabolic reprogramming in hepatocellular carcinoma: mechanisms, tumor microenvironment, and future immunotherapeutic directions","volume":"16","author":"Zhou","year":"2026","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105457_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-014192","article-title":"RNA helicase SKIV2L impedes tumor immunity by reprogramming arginine metabolism of hepatocellular carcinomas","volume":"14","author":"Zhu","year":"2026","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105457_bib66","article-title":"Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma","volume":"6","author":"Ziki","year":"2024","journal-title":"JHEP Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:46:57Z","timestamp":1793944017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"alternative-id":["S1040842826003446"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105457","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amino acid metabolic reprogramming in immunotherapy for hepatocellular carcinoma: Adaptive resistance, patient stratification, and longitudinal monitoring","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105457"}}